Valneva SE
Company Profile
Business description
Valneva SE is a vaccine company focused on developing life-saving vaccines. Its portfolio includes three vaccines for travelers. The segments of the group are Commercialized vaccines which relate to marketed vaccines, the group's vaccines IXIARO/JESPECT, DUKORAL, IXCHIQ; Covid includes development, manufacturing, & distribution related to the COVID-19 vaccine, Vaccine candidates which relate to research and development programs to generate new approvable products to generate future cash flows from product sales through partnering with pharmaceutical companies; & Technologies and services which relate to services and inventions at a commercialization stage. The company generates majority of its revenue from product sales.
Contact
6 Rue Alain Bombard
Saint-Herblain44800
FRAT: +33 228073710
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
713
Stocks News & Analysis
stocks
Our top ASX picks in every sector
stocks
Potentially catastrophic ruling for ASX company
stocks
4 charts on Nvidia’s record $4 trillion market cap
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
---|---|---|---|
All Ordinaries | 8,875.30 | 60.00 | 0.68% |
CAC 40 | 7,766.21 | 41.96 | -0.54% |
DAX 40 | 24,060.29 | 100.35 | -0.42% |
Dow JONES (US) | 44,152.42 | 307.23 | -0.69% |
FTSE 100 | 8,938.32 | 59.74 | -0.66% |
HKSE | 24,590.12 | 386.80 | 1.60% |
NASDAQ | 20,771.77 | 131.44 | 0.64% |
Nikkei 225 | 39,678.02 | 218.40 | 0.55% |
NZX 50 Index | 12,689.63 | 10.94 | 0.09% |
S&P 500 | 6,267.00 | 1.56 | -0.02% |
S&P/ASX 200 | 8,630.30 | 59.90 | 0.70% |
SSE Composite Index | 3,505.00 | 14.65 | -0.42% |